BRAF V600E mutation and papillary thyroid cancer

摘要

To the Editor Our recent multicenter study reported an association between BRAF V600E and PTC-related patient mortality. However, this association was not independent of tumor behaviors and the prognostic value of BRAF V600E was debated in an accompanying Editorial. This issue warrants further discussion in several aspects. First, the synergisticinteractionbetweenBRMFV6ooE and tumor behaviors demonstrated in our study1 suggests that BRAF V600E promotes aggressive tumor behaviors to exert its effect on mortality. Thus, multivariable analyses adjusting for tumor behaviors would artificially nullify the association between BRAF V600E and mortality, underestimating its prognostic value.